Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable
Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable, is a prominent player in the pharmaceutical industry, headquartered in Mexico. Established in 1997, the company has made significant strides in the development and distribution of high-quality pharmaceutical products across various therapeutic areas, including oncology, cardiology, and infectious diseases. With a strong presence in both domestic and international markets, Grupo Somar is recognised for its commitment to innovation and excellence. The company offers a diverse portfolio of prescription medications and over-the-counter products, distinguished by their efficacy and safety. Notably, Grupo Somar has achieved several milestones, including strategic partnerships and expansions that have solidified its market position as a trusted provider in the healthcare sector.
DitchCarbon Score
How does Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable's score of 20 is lower than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable's reported carbon emissions
Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable, headquartered in Mexico, currently does not have available carbon emissions data for the most recent year. As such, there are no specific figures regarding their emissions in kg CO2e, including Scope 1, 2, or 3 emissions. Additionally, the company has not outlined any formal reduction targets or commitments to the Science Based Targets initiative (SBTi) or other climate pledges. This absence of data suggests that Grupo Farmacéutico Somar may still be in the early stages of developing a comprehensive climate strategy or reporting framework. In the context of the pharmaceutical industry, companies are increasingly recognising the importance of addressing climate change and reducing carbon footprints. As the sector evolves, it is anticipated that Grupo Farmacéutico Somar will align with industry standards and implement initiatives to enhance their sustainability practices in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
